The main purpose of this study is to test the safety of a gene therapy. Scientists have created a gene in the laboratory that could be transferred to the cells in the body. This gene carries information to tell the cells how to make an antibody (protein). The antibody (protein) is very similar to an antibody (protein) called blinatumomab. Blinatumomab is an FDA-approved treatment for relapsed or refractory B-cell ALL. This gene therapy is not approved by the FDA, therefore is it experimental. This study tests different doses of the gene therapy to see which dose is safer in people since it has not been tested in people yet.

Do you have early-stage breast cancer that is considered low-risk by your doctor? If yes, you might be able to join a research study. In this study, we are testing if taking a lower dose of the medicine tamoxifen is a better treatment for you than the usual hormone therapy.

Have you been diagnosed with Stage 4 HER2 positive (HER2+) breast cancer? If so, you may be able to take part in a research study to test the safety and effectiveness of a sequence of drugs (a taxane plus trastuzumab plus pertuzumab followed by trastuzumab Deruxtecan, followed by tucatinib plus Ado-trastuzumab emtansine (T-DM1), followed by trastuzumab plus pertuzumab plus tucatinib) to learn whether the treatment works in treating your type of cancer. The study will help us understand whether first intensifying therapy for a specific period and then stopping treatment is safe and effective for patients who receive this therapy.

Are you a woman with a history of breast cancer (Stage 0-III)? Do you identify as Black/African-American? Do you struggle with fear or worry that your cancer may return? If you are a breast cancer survivor that identifies as Black/African-American, you may be eligible to participate in the FoRtitude Interview Study. Compensation provided.

Have you been diagnosed with HER2-low locally unresectable advanced or metastatic breast cancer? If so, you may be eligible for a study to investigate the efficacy treatment with Dato-DXd or T-DXd.

Do you have metastatic or incurable, recurrent head and neck cancer? If so, you may be able to participate in a research study to find out if a new investigational drug, in combination with pembrolizumab, can help people with advanced head and neck cancer.

Have you been diagnosed with Ovarian Cancer? Have you received cytoreductive surgery? If so, you may be able to take part in a study on a new ovarian cancer treatment. We want to find out if taking a medicine called Olaparib for one year works as well as the usual treatment for ovarian cancer. We also want to see if Olaparib can help stop the cancer from growing or coming back.

Have you been diagnosed with early stage triple negative breast cancer and not yet received treatment? If so, you may be eligible for a trial comparing the use two different regimens of chemotherapy-immunotherapy treatments prior to surgery.

Have you been diagnosed with advanced breast, lung, colorectal, or bladder cancer and does your doctor plan to send a sample of your tumor for genetic testing? If so, then you may be able to take part in a research study that looks at whether an expert review of your tumor genetic test results can help your doctor identify better treatment options or clinical trials that may be suitable for your cancer.

Have you been diagnosed with Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer? If so, you may be a good fit for a clinical trial to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab).